Truist Securities Maintains Hold on Corcept Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregory Fraser maintains a Hold rating on Corcept Therapeutics (NASDAQ:CORT) and lowers the price target from $28 to $26.
May 26, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Hold rating on Corcept Therapeutics and lowers the price target from $28 to $26.
The news directly mentions Corcept Therapeutics (NASDAQ:CORT) and the lowered price target by Truist Securities analyst Gregory Fraser. This may cause some investors to reconsider their positions, but the Hold rating suggests that the stock is not expected to have significant short-term price movement. The impact on the stock price is neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100